Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$0.96 - $2.92 $12,590 - $38,295
-13,115 Reduced 63.77%
7,451 $9,000
Q4 2022

Feb 14, 2023

SELL
$1.74 - $12.87 $713 - $5,276
-410 Reduced 1.95%
20,566 $44,000
Q3 2022

Nov 14, 2022

BUY
$7.21 - $14.88 $22,170 - $45,756
3,075 Added 17.18%
20,976 $251,000
Q2 2022

Aug 22, 2022

SELL
$5.97 - $9.97 $752 - $1,256
-126 Reduced 0.7%
17,901 $150,000
Q1 2022

May 16, 2022

BUY
$8.44 - $12.49 $4,000 - $5,920
474 Added 2.7%
18,027 $156,000
Q4 2021

Feb 14, 2022

SELL
$10.12 - $14.07 $2,884 - $4,009
-285 Reduced 1.6%
17,553 $199,000
Q3 2021

Nov 15, 2021

BUY
$7.25 - $13.23 $72,478 - $132,260
9,997 Added 127.5%
17,838 $225,000
Q2 2021

Aug 12, 2021

SELL
$8.0 - $9.75 $4,992 - $6,084
-624 Reduced 7.37%
7,841 $63,000
Q1 2021

May 17, 2021

SELL
$8.63 - $10.94 $1,829 - $2,319
-212 Reduced 2.44%
8,465 $79,000
Q3 2020

Nov 13, 2020

SELL
$11.3 - $14.75 $16,317 - $21,299
-1,444 Reduced 14.27%
8,677 $107,000
Q2 2020

Aug 14, 2020

BUY
$9.52 - $15.98 $28,502 - $47,844
2,994 Added 42.01%
10,121 $132,000
Q1 2020

May 14, 2020

SELL
$8.0 - $15.48 $15,616 - $30,216
-1,952 Reduced 21.5%
7,127 $72,000
Q4 2019

Feb 13, 2020

BUY
$14.82 - $26.79 $14,167 - $25,611
956 Added 11.77%
9,079 $141,000
Q3 2019

Nov 13, 2019

BUY
$16.02 - $22.47 $60,859 - $85,363
3,799 Added 87.86%
8,123 $137,000
Q2 2019

Aug 14, 2019

BUY
$16.12 - $22.89 $41,541 - $58,987
2,577 Added 147.51%
4,324 $96,000
Q1 2019

May 15, 2019

BUY
$17.58 - $23.97 $30,712 - $41,875
1,747 New
1,747 $38,000

Others Institutions Holding GOSS

About Gossamer Bio, Inc.


  • Ticker GOSS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,954,000
  • Market Cap $80.8M
  • Description
  • Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...
More about GOSS
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.